Physician profile
Tarun Narang
NPI 1205904448
$11,336.98
in general payments reported to CMS, 2019-2025
48 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $1,121 · 2021: $1,496 · 2022: $1,976 · 2023: $1,419 · 2024: $1,942 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,182 · Education: $63.23 · Travel and Lodging: $12.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.98 |
| Education | $63.23 |
| Travel and Lodging | $12.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,707.89 | 2019-2025 | |
| Janssen Biotech, INC. | $1,119.52 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $948.14 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $851.82 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $671.87 | 2021-2024 | Zeposia |
| Pfizer INC. | $553.75 | 2019-2025 | |
| Qol Medical, LLC | $542.96 | 2019-2025 | Sucraid, Sucraid |
| Amgen INC. | $356.04 | 2020-2025 | Uplizna, Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $287.80 | 2019-2025 | Rebyota |
| Evoke Pharma, INC. | $272.22 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $255.97 | 2020-2023 | Linzess |
| Genzyme Corporation | $232.55 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $179.07 | 2024-2025 | Zenpep |
| 3-D Matrix, INC. | $144.11 | 2024 | |
| Redhill Biopharma INC. | $136.97 | 2020-2024 | Talicia, Aemcolo, Movantik |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $136.62 | 2019-2024 | |
| Angiodynamics, INC. | $129.14 | 2023 | Nanoknife |
| Celltrion USA INC. | $128.04 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $124.46 | 2019-2024 | Dificid |
| Apollo Endosurgery US INC | $121.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.33 | 2022-2025 | Dupixent |
| Medtronic, INC. | $117.35 | 2023-2024 | Interstim |
| Vivus LLC | $113.84 | 2021-2025 | Qsymia, Pancreaze |
| Nestle Healthcare Nutrition INC. | $104.61 | 2021-2023 | |
| Lilly USA, LLC | $98.02 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $88.66 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $86.92 | 2022-2025 | Sutab, Suflave |
| Ucb, INC. | $85.43 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $77.56 | 2020-2024 | |
| Olympus America INC. | $69.61 | 2024 | Visiglide |
| Alnylam Pharmaceuticals INC. | $67.71 | 2021-2023 | Givlaari |
| Organon LLC | $42.80 | 2021-2025 | Hadlima |
| Madrigal Pharmaceuticals | $39.56 | 2024 | Rezdiffra |
| Dova Pharmaceuticals | $31.00 | 2019 | |
| Conmed Corporation | $29.87 | 2025 | Conmed Biliary |
| Intra-Sana Laboratories | $29.13 | 2021-2022 | |
| Shield Therapeutics INC | $28.67 | 2024 | |
| Novo Nordisk INC | $24.74 | 2025 | Wegovy |
| Shionogi INC | $24.52 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $24.11 | 2024 | Voquezna |
| Sandoz INC. | $23.19 | 2024 | Hyrimoz |
| Ultragenyx Pharmaceutical INC. | $19.12 | 2024 | Dojolvi |
| Fresenius Kabi USA, LLC | $17.43 | 2023 | Idacio |
| Daiichi Sankyo INC. | $16.37 | 2021 | |
| Exact Sciences Corporation | $15.95 | 2023 | Cologuard Collection Kit |
| W. L. Gore & Associates, INC. | $13.50 | 2023 | Gore Cardioform Septal Occluder |
| Allergan, INC. | $13.39 | 2020 | |
| Alfasigma USA, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Narang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.